Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:LMAT) with a Outperform and maintains $95 pr...
Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:LMAT) with a Outperform and maintains $95 pr...
Cantor Fitzgerald analyst Ross Osborn maintains LeMaitre Vascular (NASDAQ:LMAT) with a Neutral and raises the price target f...
Barrington Research analyst Michael Petusky upgrades LeMaitre Vascular (NASDAQ:LMAT) from Market Perform to Outperform and a...
LeMaitre Vascular (NASDAQ:LMAT) is looking for Q3 GAAP EPS of $0.54-$0.59 vs $0.54 analyst estimate. sees sales of $61.200 mill...
LeMaitre Vascular (NASDAQ:LMAT) raises FY2025 GAAP EPS guidance from $2.07-$2.24 to $2.23-$2.37 vs $2.15 analyst estimate. Rais...
LeMaitre Vascular (NASDAQ:LMAT) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $0....
